- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01268384
Neoadjuvant FDR GX in Locally Advanced Pancreatic Cancer
Phase II Study of Fixed Dose Rate Gemcitabine Plus Capecitabine in Locally Advanced Pancreatic Cancer
The rationale for phase II trial of neoadjuvant fixed dose rate gemcitabine plus capecitabine for patients with LAPC includes the following: First, obtaining a sufficient tumor down-staging to procure R0/R1 resection, reported to be one of the most significant prognostic factors for survival; second, providing an observation period to exclude from surgery those patients with rapidly progressive disease there by to help select patients for surgery who have the greatest likelihood of a favorable postoperative outcome; third, eliminating micrometastatic disease, that is likely present in most patients, earlier than adjuvant setting and preventing post-surgical growth spurts; fourth, adjuvant therapy given in the neoadjuvant setting is better tolerated, as the patient has not recently undergone a major operation; and the last, the lack of widely accepted optimal preoperative or palliative approach in patients with LAPC, the majority of whom may not be operated on.
The primary goal is to determine the R0 resection rate of the neoadjuvant fixed dose rate (FDR) gemcitabine-capecitabine combination chemotherapy in patients with borderline resectable or unresectable locally advanced pancreatic adenocarcinoma.
The secondary goals are to assess progression-free survival (PFS) and OS (overall survival) in these patients and to assess adverse events of these neoadjuvant treatments.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 2
Kontakter och platser
Studieorter
-
-
-
Seoul, Korea, Republiken av, 138-736
- Asan Medical Center
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Histologically or cytologically documented pancreatic adenocarcinoma
- Clinical T3 or T4 tumor according to AJCC staging system
- Tumors considered as borderline resectable or unresectable disease assessed by multidisciplinary team including pancreatic surgeon, gastroenterologist specializing in pancreas, medical oncologist, and radiation oncologist
- Age 18 years or older
- ECOG performance status 2 or less
Adequate organ function
- Adequate bone marrow function (WBCs> 3,500/µL, absolute neutrophil count [ANC]> 1,500/µL, hemoglobin > 9.0 g/dL, and platelets > 100,000/µL)
- Adequate kidney function (creatinine < 1.5 mg/dL)
- Adequate liver function (bilirubin < 1.5 mg/dL [<2.5 mg/dL for patients with obstructive jaundice due to pancreatic cancer with adequate decompression], transaminases levels < 3 times the upper normal limit)
- Patients must not have psychological, familial, sociological or geographical conditions which do not permit medical follow-up and compliance with this study
- Women of childbearing potential must have a negative pregnancy test on admission. Post-menopausal women must have been amenorrheic for at least 12 months to be considered of non-childbearing potential. Men and women of reproductive potential must have agreed to use an effective method of contraception while on treatment and for 6 months after study treatment
- The patient must be able to understand the study and has given written informed consent to participate in the study
Exclusion Criteria:
- Other tumor type than adenocarcinoma
- Evidence of gastrointestinal bleeding or obstruction
- Presence of the clinically relevant ascites or distant metastases
- Past or concurrent history of malignant neoplasm, except for curatively treated non-melanoma skin cancer or in situ carcinoma of the cervix uteri
- Pregnant or lactating women, women of childbearing potential not employing adequate contraception
- Hypersensitivity to any of the study drugs or ingredients
Other serious illness or medical conditions
- Unstable cardiac disease despite treatment, myocardial infarction within 6 months prior to study entry
- History of significant neurologic or psychiatric disorders including dementia or seizures
- Active uncontrolled infection
- Pre-existing clinically significant diarrhea
- Active peptic ulcer
- Severe hypercalcemia of 12 mg/dL uncontrolled with bisphosphonates
- Active disseminated intravascular coagulation
- Other serious underlying medical conditions which could impair the ability of the patient to participate in the study
- Concomitant or administration of any other experimental drug under investigation within 3 weeks before the study
- Concomitant chemotherapy, hormonal therapy, or immunotherapy
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: FDR_GX
Fixed dose rate gemcitabine plus capecitabine every 3 weeks for 3-9 cycles
|
Gemcitabine 1,250 mg/m2 mixed with 0.9% saline 500 ml i.v. for 10 mg/m2/min on D1 and D8 Capecitabine 950 mg/m2 b.i.d.
po from D1 to D14 every 21 days
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
R0 resection rate
Tidsram: 6 months
|
Microscopic complete resection rate after neoadjuvant chemotherapy
|
6 months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Adverse events associated with neoadjuvant chemotherapy
Tidsram: 6 months
|
NCI CTCAE v.3.0 based AEs
|
6 months
|
Overall survival
Tidsram: 2 years
|
Overall survival after enrollment
|
2 years
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Jae-Lyun Lee, MD, PhD, Asan Medical Center
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Matsmältningssystemets sjukdomar
- Neoplasmer
- Neoplasmer efter plats
- Sjukdomar i det endokrina systemet
- Neoplasmer i matsmältningssystemet
- Neoplasmer i endokrina körtel
- Bukspottkörtelsjukdomar
- Pankreatiska neoplasmer
- Läkemedels fysiologiska effekter
- Molekylära mekanismer för farmakologisk verkan
- Anti-infektionsmedel
- Antivirala medel
- Enzyminhibitorer
- Antimetaboliter, antineoplastiska
- Antimetaboliter
- Antineoplastiska medel
- Immunsuppressiva medel
- Immunologiska faktorer
- Gemcitabin
- Capecitabin
Andra studie-ID-nummer
- APBCC_01
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Bukspottskörtelcancer
-
Tianjin Medical University Cancer Institute and...Har inte rekryterat ännuPDAC - Pancreatic Ductal Adenocarcinoma
-
Sun Yat-sen UniversityRekryteringPDAC - Pancreatic Ductal AdenocarcinomaKina
-
Azienda Ospedaliera Universitaria Integrata VeronaRekryteringPDAC - Pancreatic Ductal AdenocarcinomaItalien
-
Cedars-Sinai Medical CenterRekryteringPDAC - Pancreatic Ductal AdenocarcinomaFörenta staterna
-
Azienda Ospedaliera Universitaria Integrata VeronaRekryteringPDAC - Pancreatic Ductal AdenocarcinomaItalien
-
Radboud University Medical CenterDutch Cancer SocietyRekryteringPDAC - Pancreatic Ductal AdenocarcinomaNederländerna
-
Imperial College LondonThe Leeds Teaching Hospitals NHS Trust; Sheffield Teaching Hospitals NHS... och andra samarbetspartnersRekryteringBukspottskörtelcancer | PDAC - Pancreatic Ductal AdenocarcinomaStorbritannien
-
Chinese PLA General HospitalRekryteringPankreatiska neoplasmer | Bukspottskörtelcancer | Bukspottkörtelcancer | PDAC - Pancreatic Ductal AdenocarcinomaKina
-
Andrei IagaruInte längre tillgängligKarcinoida tumörer | Islet Cell (Pancreatic NET) | Andra neuroendokrina tumörerFörenta staterna
-
Mayo ClinicRekryteringBukspottskörtelcancer | Duktalt adenokarcinom i bukspottkörteln | PDAC | PDAC - Pancreatic Ductal AdenocarcinomaFörenta staterna
Kliniska prövningar på Gemcitabine plus Capecitabine
-
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Avslutad
-
Swiss Group for Clinical Cancer ResearchAvslutadSmärta | Lever cancer | Gallblåscancer | Extrahepatisk gallvägscancerSchweiz
-
Sun Yat-sen UniversityChengdu Biostar PharmaceuticalsHar inte rekryterat ännuBröstneoplasmer | Lokalt avancerad eller metastaserad bröstcancerKina
-
Rutgers, The State University of New JerseyRekryteringBukspottskörtelcancerFörenta staterna
-
Jiangsu HengRui Medicine Co., Ltd.OkändHER2 positiv metastaserande bröstcancerKina
-
Assiut UniversityHar inte rekryterat ännu
-
University of Southern CaliforniaNational Cancer Institute (NCI)RekryteringCancer | Metastatisk | Bröst | Trippel negativ | Disseminerad tumörcellFörenta staterna
-
Sun Yat-sen UniversityRekryteringNasofaryngealt karcinomKina
-
Asan Medical CenterSeoul St. Mary's Hospital; Severance Hospital; Bundang CHA HospitalAvslutadKolangiokarcinom | Gallvägscancer | Adjuvant kemoterapi | Capecitabin | Gemcitabin | CisplatinKorea, Republiken av
-
Vejle HospitalAvslutadKolangiokarcinomDanmark